Alzheimer’s isn’t just one problem—it’s a tangled mix of biology, aging, and overall health. That’s why drugs targeting a single factor have fallen short, even as new treatments show modest benefits. Scientists are now pushing toward multi-pronged strategies, from gene editing to brain-cell rejuvenation and gut health interventions. The goal: stop treating Alzheimer’s as one disease and start tack
A common eye-health nutrient, zeaxanthin, may also help the body fight cancer more effectively. Scientists discovered it strengthens T cells and enhances the impact of immunotherapy treatments. Found in everyday vegetables and supplements, it’s safe, accessible, and shows strong potential as a cancer therapy booster. Human trials are the next step.
Envision Pharma Group has hired clinical research veteran Nick Jones as president of its Envision Medical Communications (EMC) business.
The wait is over. Fierce Biotech has unveiled its ranking of the top 10 pharma R&D budgets of 2025. In this episode of "The Top Line," Darren Incorvaia and Eric Sagonowsky break down the biggest trends and what’s changed year over year.
Portuguese biopharma Bial is launching a year-long disease awareness campaign that’s intended to boost understanding of Parkinson’s disease and its often subtle and early-stage symptoms.
In this week's STATus Report, host Alex Hogan dives into how sports betting apps hook users — and how he himself fell for some too-good-to-be-true promotions.
“What MAHA has built, in a relatively short time, is social capital,” writes Monica L. Wang.
“In my most honest of moments, what I want from the medical community is the chance to trust it again,” a MAHA advocate writes.
Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives with the goal of roughly tripling their footprint by 2030.
Too much information, uncertainty and financial worries are hitting Americans when it comes to making important choices for their health.
Amneal and BioCorRx have earned the ire of the FDA’s Office of Prescription Drug Promotion (OPDP), with both being hit by accusations of violating the agency’s drug marketing rules.
Cancer drugs known as BET inhibitors once looked like a breakthrough, but in real patients they’ve often fallen short. New research reveals a key reason why: two closely related proteins, BRD2 and BRD4, don’t actually do the same job. Instead, BRD2 acts like a “stage manager,” preparing genes for activation, while BRD4 triggers the final step that turns them on. By blocking both at once, current d
A breakthrough in microbiome research could change how colorectal cancer is detected—no colonoscopy required. Scientists used AI to map gut bacteria at an unprecedented level of detail, revealing subtle microbial patterns linked to cancer. By analyzing simple stool samples, their method identified 90% of cases, rivaling one of medicine’s most trusted diagnostic tools.
Health tech companies are working to make medical records more portable, but so far, the effort is voluntary.
The panel had become a flashpoint as RFK Jr.'s health department worked to limit the number of recommended childhood shots.
This week on "The Readout LOUD": Why is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA?
Democrats are focused on health care affordability as costs keep climbing.
Takeda ended its neurogenerative disease partnership with Denali Therapeutics. Merck & Co. and Zhifei scrapped a minimum purchase requirement in their vaccine distribution agreement. Shionogi secured funding from the U.S. government to boost the domestic supply of an antibiotic. And more.
CAR-T therapy is toting up more remissions in autoimmune disease, and generating a flood of experimentation and investment.
Vanda is kicking off a phase 3 trial which will evaluate the efficacy and safety of its newly approved motion sickness drug Nereus in patients receiving a high dose of a GLP-1 agonist. The primary endpoint is the proportion of patients free from vomiting episodes.